Omega Diagnostics receives deferred £4m from CD4 sale
Cambridge Nutritional Science
4.00p
16:55 24/04/24
0.00%
0.00p
Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
FTSE AIM All-Share
754.69
16:50 24/04/24
n/a
n/a
Health Care Equipment & Services
11,761.33
17:09 24/04/24
0.20%
23.76
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
“Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m,” the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.